Rui Xu, PhD
Senior Vice President, Drug Discovery
Rui joined BridgeBio Pharma in February 2020 and is now Senior Vice President of Drug Discovery at BBOT where he leads the PI3Kα breaker project. Prior to BridgeBio, Rui was a Research Fellow at Peloton Therapeutics and a Principal Research Investigator at Array BioPharma. Rui led or made key contributions to multiple programs that resulted in the discovery of development candidates including the HIf2α inhibitor Belzutifan® and the Akt inhibitor ipatasertib.
Rui earned his PhD in Organic Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and a BS in Chemistry from Nankai University. He completed his postdoctoral training at College of Pharmacy, University of Kentucky.